| Mycophenolate Mofetil and Abacavir Treatment in HIV Patients With Failed Anti-HIV Treatment (NCT00021489) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluating Immune Function Tests in People With HIV (NCT00067795) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients (NCT00000899) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals (NCT00000684) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV Therapy (NCT00000905) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease (NCT00000656) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS (NCT00000644) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes (NCT00000645) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) (NCT00051077) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Randomized Dose/Formulation Comparison Study of SC-52151 (NCT00000806) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy (NCT00038259) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen (NCT00014937) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications (NCT00001078) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients (NCT00007202) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452 (NCT00006495) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection (NCT00000739) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS (NCT00000981) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs (NCT00001067) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluation of Patients Who Have Not Had Success With Zidovudine (NCT00001025) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI) (NCT00000742) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Methylprednisolone in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Children With AIDS (NCT00000741) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs (NCT00017758) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection (NCT00000919) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals (NCT00000648) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients (NCT00000768) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Dideoxycytidine Plus Zidovudine in the Treatment of AIDS or Advanced AIDS Related Complex (ARC) (NCT00000978) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin (NCT00000778) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC (NCT00026624) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines (NCT00000746) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa (NCT00006298) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children (NCT00000827) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults (NCT00000853) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effect of Anti-HIV Therapy on Fat Metabolism in HIV-Positive Patients (NCT00001102) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Comparison of Two Tests for Anti-HIV Drug Resistance (NCT00006490) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Dideoxycytidine in HIV-Infected Patients (NCT00000997) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315 (NCT00000891) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects (NCT00000845) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma (NCT00000681) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Prevalence of Hepatitis C Virus Infection in HIV-Infected Children (NCT00037076) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients (NCT00000824) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants (NCT00038480) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients (NCT00046267) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine (NCT00001136) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Acceptability of a Vaginal Microbicide (NCT00111943) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Growth Hormone Treatment of Children With HIV-Associated Growth Failure (NCT00006143) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and Neutropenia (NCT00008840) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients (NCT00000890) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine (NCT00000828) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients (NCT00000748) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Effects of SQ109 on QTc Interval in Healthy Subjects (NCT01874314) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy (NCT00107549) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens (NCT00000935) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children (NCT00000773) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs (NCT00001083) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS (NCT00000992) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine (NCT02684383) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women (NCT00000864) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies (NCT00001016) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children (NCT00000913) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) Infection (NCT00000702) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity (NCT00000977) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection (NCT00000636) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals (NCT00272493) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV (NCT00051090) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers (NCT00001090) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3 (NCT00000712) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection (NCT00000984) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers (NCT00001055) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease (NCT00000626) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone (NCT00000788) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160 (NCT00000956) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma (NCT00000954) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN) (NCT00000819) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission (NCT00021671) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluating the Safety and Immune Response of DNA/MVA Vaccines in HIV-1-Infected Young Adults Taking Anti-HIV Medications (NCT01909414) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea (NCT00001018) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn) (NCT00000631) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission (NCT00053612) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Changing to Nonprotease Inhibitor Treatment to Improve Side Effects (NCT00021463) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection (NCT00000793) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma (NCT00001114) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects (NCT00000740) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults (NCT00054860) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA) (NCT00000886) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection (NCT00000872) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3 (NCT00000857) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Correlates of Protection in Ghana (NCT00138307) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Heterosexual HIV Transmission Study (HATS). Prospective Cohort Study (NCT00000787) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Zidovudine in the Treatment of Patients With Early AIDS Related Complex (NCT00001011) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication (NCT00006578) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma (NCT00000725) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects (NCT00000713) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3) (NCT00000781) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients (NCT00000962) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children (NCT00000901) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients (NCT00050895) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV (NCT00033163) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults (NCT00000904) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy (NCT00000728) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320 (NCT00000885) | National Institute of Allergy and Infectious Diseases (NIAID) | |